GlassScriptPhysician profile
Laura Mae Birnbaum
NPI 1053309088
$6,314.55
in general payments reported to CMS, 2019-2025
33 companies · $805 in 2025
The $805 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $915 · 2021: $993 · 2022: $825 · 2023: $685 · 2024: $956 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,949.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $592.53 | 2019-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $389.95 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $383.35 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $349.77 | 2021-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $309.76 | 2019-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $284.60 | 2024-2025 | Korlym |
| Pfizer INC. | $222.93 | 2019-2025 | |
| Abbott Laboratories | $165.93 | 2023-2024 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $164.74 | 2020-2025 | |
| Allergan, INC. | $160.23 | 2019-2020 | |
| Astellas Pharma US INC | $143.41 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $141.36 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.29 | 2021-2025 | Jardiance |
| Mylan Specialty L.P. | $115.70 | 2022-2023 | Yupelri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $110.27 | 2019-2025 | Capvaxive, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $100.60 | 2022-2024 | Quviviq |
| Eisai INC. | $82.84 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.46 | 2022 | |
| Exact Sciences Corporation | $73.50 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $70.35 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $49.43 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.72 | 2021-2022 | |
| Genentech USA, INC. | $29.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $26.23 | 2019 | |
| Organon LLC | $24.37 | 2025 | Nexplanon |
| Hologic Sales and Service, LLC | $22.33 | 2019 | |
| Halozyme INC | $21.98 | 2023 | |
| Genzyme Corporation | $20.19 | 2023 | |
| Axsome Therapeutics, INC. | $20.10 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $16.34 | 2021 | |
| Tolmar, INC. | $14.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Birnbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.